Characterized by hypermethylation, a high frequency of AML‐MR mutations, and unstable chromosomal changes, UAMOCS1 patients exhibit lower response rates to conventional therapies and poor prognosis. The gene discussed is NR3C2; the disease is acute myeloid leukemia.